Development of an Enzyme Immunoassay for Delta Sleep-Inducing Peptide (DSIP) and Its Use in the Determination of the Metabolic Clearance Rate of DSIP Administered to Dogs

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

A method for the enzyme immunoassay (EIA) of delta sleep-inducing peptide (DSIP) has been developed and applied to determine the metabolic clearance rate and biological half-life of DSIP administered to dogs. Antisera to DSIP conjugated to bovine serum albumin were raised in rabbits and proved to be specific for the C-terminus of the peptide. DSIP conjugated to horseradish peroxidase served as the labeled antigen in the EIA and enzyme activity was determined by fluorophotometry. The assay sensitivity was approximately 30 pg/ml. 1 or 2 mg of DSIP was injected intravenously into 4 anesthetized dogs and blood was taken at 5-min intervals. Unextracted plasma was subjected to the EIA directly and showed parallel displacement curves to the standards. DSIP was found to have a rapid disappearance with a mean metabolic clearance rate of 30.7 ± 2.5 ml/kg · min and a mean half-life of 4.0 ± 0.7 min in the dogs. Additional measurements of the metabolic parameters in a monkey and 3 rats treated similarly revealed a rapid in vivo clearance of DSIP from plasma with a half-life of 2.9 and 2.0 ± 0.54 min, respectively.

Related collections

Author and article information

Journal

Journal ID (publisher-id): NEN

Journal ID (nlm-ta): Neuroendocrinology

Journal ID (doi): 10.1159/issn.0028-3835

Title: Neuroendocrinology

Publisher: S. Karger AG

ISSN (Print): 0028-3835

ISSN (Electronic): 1423-0194

Publication date Subscription-year: 1984

Publication date (Print): 1984

Publication date (Electronic): 28 March 2008

Volume: 39

Issue: 1

Pages: 39-44

Affiliations

aDivision of Diagnostics, National Center for Nervous, Mental and Muscular Disorders, Kodaira, and ^bDepartment of Psychology, Tokyo Metropolitan Institute for Neurosciences, Fuchu, Tokyo, Japan

Article

Publisher ID: 123952 Other ID: Neuroendocrinology 1984;39:39–44

DOI: 10.1159/000123952

PubMed ID: 6379493

SO-VID: 14dae2b8-606e-4896-b540-5faad859e66f

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 31 May 1983

Date accepted : 01 December 1983

Page count

Pages: 6

Comments

Comment on this article

scite_